Beneficial impact of first-line mogamulizumab-containing chemotherapy in adult T-cell leukaemia-lymphoma.

Takafumi Shichijo, Kisato Nosaka, Hiro Tatetsu, Yusuke Higuchi, Shinya Endo, Yoshitaka Inoue, Kosuke Toyoda, Yoshitaka Kikukawa, Toshiro Kawakita, Jun-Ichirou Yasunaga, Masao Matsuoka

British journal of haematology 2022 Sep

filter terms:

Chemotherapy in combination with mogamulizumab (Mog) was approved in Japan in 2014 for untreated aggressive adult T-cell leukaemia-lymphoma (ATL), but the survival benefit remains unclear. Therefore, we retrospectively analysed clinical outcomes in 39 transplant-ineligible patients with untreated aggressive ATL at Kumamoto University Hospital between 2010 and 2021. The probability of four-year overall survival was 46.3% in the first-line Mog-containing treatment group compared to 20.6% in the chemotherapy-alone group (p = 0.033). Furthermore, this survival benefit was observed even in the elderly. In conclusion, first-line Mog-containing treatment can be a promising strategy for transplant-ineligible patients with ATL, especially in the elderly. © 2022 British Society for Haematology and John Wiley & Sons Ltd.

Citation

Takafumi Shichijo, Kisato Nosaka, Hiro Tatetsu, Yusuke Higuchi, Shinya Endo, Yoshitaka Inoue, Kosuke Toyoda, Yoshitaka Kikukawa, Toshiro Kawakita, Jun-Ichirou Yasunaga, Masao Matsuoka. Beneficial impact of first-line mogamulizumab-containing chemotherapy in adult T-cell leukaemia-lymphoma. British journal of haematology. 2022 Sep;198(6):983-987